In the last trading session, 6.99 million shares of the Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) were traded, and its beta was 1.04. Most recently the company’s share price was $13.49, and it changed around $0.14 or 1.05% from the last close, which brings the market valuation of the company to $15.12B. TEVA currently trades at a discount to its 52-week high of $13.93, offering almost -3.26% off that amount. The share price’s 52-week low was $7.09, which indicates that the current value has risen by an impressive 47.44% since then. We note from Teva- Pharmaceutical Industries Ltd. ADR’s average daily trading volume that its 10-day average is 9.71 million shares, with the 3-month average coming to 10.93 million.
Teva- Pharmaceutical Industries Ltd. ADR stock received a consensus recommendation rating of Hold, based on a mean score of 1.92. If we narrow it down even further, the data shows that 5 out of 26 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 17 recommended TEVA as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Teva- Pharmaceutical Industries Ltd. ADR is expected to report earnings per share of $0.52 for the current quarter.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) trade information
Instantly TEVA has showed a green trend with a performance of 1.05% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently up 29.21% year-to-date, but still down -0.37% over the last five days. On the other hand, Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) is 12.32% up in the 30-day period. We can see from the shorts that 15.39 million shares have been sold at a short interest cover period of 1.17 day(s).
The consensus price target as assigned by Wall Street analysts is $13, which translates to bulls needing to decrease their stock price by -3.77% from its current value. Analyst projections state that TEVA is forecast to be at a low of $10 and a high of $19.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) estimates and forecasts
Teva- Pharmaceutical Industries Ltd. ADR share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 34.36 percent over the past six months and at a -7.03% annual growth rate that is well below the industry average of 5.00%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 30.00% in revenue this quarter, and will report an increase of 3.60% in the next quarter. The year-over-year growth rate is expected to be -0.20%, down from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of $3.76 billion in revenue for the current quarter. 7 analysts expect Teva- Pharmaceutical Industries Ltd. ADR to make $4 billion in revenue for the quarter ending Jun 2024. Analysts predict that the company’s current quarter sales will jump, forecast at 3.70%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 26.63%. Teva- Pharmaceutical Industries Ltd. ADR earnings are expected to increase by -6.30% in 2024, but the outlook is positive 1.60% per year for the next five years.
TEVA Dividends
Teva- Pharmaceutical Industries Ltd. ADR’s next quarterly earnings report is expected to be released in April.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.00% of Teva- Pharmaceutical Industries Ltd. ADR shares, and 53.42% of them are in the hands of institutional investors. The stock currently has a share float of 53.42%. Teva- Pharmaceutical Industries Ltd. ADR stock is held by 621 institutions, with Blackrock Inc. being the largest institutional investor. By Jun 29, 2023, it held 3.59% of the shares, which is about 40.29 million shares worth $303.38 million.
Phoenix Holdings Ltd., with 3.01% or 33.7 million shares worth $253.79 million as of Jun 29, 2023, holds the second largest percentage of outstanding shares.
Fundamental Investors Inc and iShares Core MSCI EAFE ETF were the top two Mutual Funds as of Sep 29, 2023. The former held 6.73 million shares worth $68.62 million, making up 0.60% of all outstanding shares. On the other hand, iShares Core MSCI EAFE ETF held roughly 6.19 million shares worth around $60.43 million, which represents about 0.55% of the total shares outstanding.
